Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

SGLT2 inhibitor

This page shows the latest SGLT2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

AZ says Farxiga cuts kidney disease in type 2 diabetes

AZ says Farxiga cuts kidney disease in type 2 diabetes

Helps in SGLT2 inhibitor battle with Jardiance. AstraZeneca has more data showing that its SGLT2 inhibitor Farxiga can prevent complications of type 2 diabetes, this time showing it can reduce the ... data that could help it consolidate its position in

Latest news

  • Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12% Lilly’s Trulicity cuts heart and kidney risks in diabetes by 12%

    Results from phase 3 trials of the drug presented at the ADA found that it was better at maintaining glucose control than Lilly and Boehringer Ingelheim’s oral SGLT2 inhibitor Jardiance

  • Lilly claims cluster headache first for CGRP drug Emgality Lilly claims cluster headache first for CGRP drug Emgality

    IL-23 inhibitor Skyrizi (risankizumab), and top-selling diabetes therapy Trulicity (dulaglutide) is also under pricing pressure. ... The company has filed for approval of another diabetes product to try to shore up the franchise – a fixed-dose triple

  • Genfit presses the gas on NASH with combo trials Genfit presses the gas on NASH with combo trials

    agonist plus a combination with an SGLT2 inhibitor, to try to offer “optimal benefits” to NASH patients. ... moment. It’s notable that Gilead now has a two disappointing late-stage trial readouts for its ASK1 inhibitor selonsertib in NASH, while

  • J&J’s Invokana first SGLT2 to show kidney disease benefits J&J’s Invokana first SGLT2 to show kidney disease benefits

    The results from the phase 3 CREDENCE study are an important boost for Invokana, which is trailing behind other competitors in the SGLT2 inhibitor class in terms of market share. ... The trial puts Invokana one step ahead of rivals, such as AstraZeneca,

  • Success for AZ, setback for Sanofi in type 1 diabetes Success for AZ, setback for Sanofi in type 1 diabetes

    The approval means AZ’s SGLT2 inhibitor Forxiga (dapagliflozin) can be used in the EU in overweight or obese type 1 diabetes patients who are struggling to keep control of their ... Sanofi has been less fortunate with its US marketing application for

More from news
Approximately 1 fully matching, plus 67 partially matching documents found.

Latest Intelligence

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    Company acquisition. Marketed BTK inhibitor for haematological cancers pipeline incl. 3 products in clinic. ... 165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives

  • Pharma deals during April 2013 Pharma deals during April 2013

    The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... Clearly the pressure is on, the announcement coming only a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Quick links

Infographics

Multimedia